Generic Trisenox Availability
Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):
TRISENOX (arsenic trioxide - injectable; injection)
Has a generic version of Trisenox been approved?
No. There is currently no therapeutically equivalent version of Trisenox available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,723,351
Issued: April 20, 2004
Inventor(s): Raymond P.; Warrell, Jr. & Pier Paolo; Pandolfi & Janice L.; Gabrilove
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,855,339
Issued: February 15, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,861,076
Issued: March 1, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,884,439
Issued: April 26, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,982,096
Issued: January 3, 2006
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
-
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 8,273,379
Issued: September 25, 2012
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:- November 10, 2018✓
- November 10, 2018
See also...
- Trisenox Consumer Information (Wolters Kluwer)
- Trisenox Consumer Information (Cerner Multum)
- Trisenox Advanced Consumer Information (Micromedex)
- Trisenox AHFS DI Monographs (ASHP)
- Arsenic Consumer Information (Wolters Kluwer)
- Arsenic trioxide Consumer Information (Cerner Multum)
- Arsenic trioxide Intravenous Advanced Consumer Information (Micromedex)
- Arsenic Trioxide AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
